Day One Biopharmaceuticals’ fair value estimate remains steady at $22.25 per share, even as the Mersana acquisition adds a second antibody drug conjugate and broadens its oncology platform. While the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback